Use of L-carnitine in general medical practice
Issue:
4
Year:
2019
The paper presents the results of a number of experimental and clinical studies proving the prospects for using L-carnitine in the clinic of internal diseases. Due to its antioxidant and antihypoxant properties, L-carnitine used in addition to the main etiopathogenetic therapy is prescribed by cardiologists, nephrologists, neurologists, and gerontologists. The experimental studies previously conducted by the authors showed no effect of L-carnitine on cytochrome P450 3A4 activity, which lowers the risk of P450 (CYP) 3A4 metabolic drug interactions. When used as part of comprehensive pharmacotherapy, L-carnitine has an increased safety profile in comorbid patients taking the drug.
Keywords:
cardiology
L-carnitine
cytochrome P450 (CYP) 3А4
chronic heart failure
myocardial infarction
chronic renal failure
drug interactions
antioxidant
antihypoxant
References:
- Kukes V.G., Sychev D.A. Personalizirovannaja meditsina: novye vozmozhnosti dlja povyshenija bezopacnocti fapmakotepapii // Remedium. – 2010; 10: 38–40 [Kukes V.G., Sychev D.A. Personalized medicine: new possibilities to improve the safety of pharmacotherapy // Chem. – 2010; 10: 38–40 (in Russ.)].
- Maxova A.A. Vlijanie nagpyzochnyx doz vitaminov gruppy B na fapmakokinetiky i fapmakodinamiky NPVP. Dis. ... kand. med. nayk. M., 2010; 107 s. [Makhova AA. Influence of therapeutic doses of vitamins B on the pharmacokinetics and pharmacodynamics of the NSAIDs. Diss. ... PhD. M., 2010; 107 p. (in Russ.)].
- Rebouche C Carnitine. In: Shils M.E., Shike M., Ross A.C., Caballero B., Cousins R.J., eds. Modern Nutrition in Health and Disease. 10th ed. / Philadelphia: Lippincott, Williams & Wilkins, 2006; 537–44.
- Rebouche C. Kinetics, pharmacokinetics, and regulation of L-carnitine and acetyl-L-carnitine metabolism // Ann. NY Acad. Sci. – 2004; 1033: 30–41.
- De Grandis D., Minardi C. Acetyl-L-carnitine (levacecarnine) in the treatment of diabeic neuropathy. A long-term, randomised, doubleblind, placebo-controlled study // Drugs RD. – 2002; 3 (4): 223–31.
- Gross C., Henderson L., Savaiano D. Uptake of L-carnitine, D-carnitine and acetyl-L-carnitine by isolated guinea-pig enterocytes // Biochim Biophys Acta. – 1986; 886 (3): 425–33.
- Foster D. The role of the carnitine system in human metabolism // Ann. NY Acad. Sci. – 2004; 1033: 1–16.
- Astashkin E.I., Glezer M.G. Rol' L-karnitina v energetichesokm obmene kardiomiotsitov i lechenii zabolevanij serdechno-sosudistoj sistemy // Kardiologija i serdechno-sosudistaja hirurgija. – 2012; 6 (2): 58–65 [Astashkin E.I., Glezer M.G. Effect of L-carnitine on oxydative stress at cardiovascular diseases // Cardiology and Cardiovascular Surgery. – 2012; 6 (2): 58–65 (in Russ.)].
- Lombard K., Olson A., Nelson S. et al. Carnitine status of lactoovovegetarians and strict vegetarian adults and children // Am. J. Clin. Nutr. – 1989; 50 (2): 301–6.
- Nezu J., Tamai I., Oku A. et al. Primary systemic carnitine deficiency is caused by mutations in a gene encoding sodium ion-dependent carnitine transporter // Nat Genet. – 1999; 21 (1): 91–4.
- Stanley C. Carnitine deficiency disorders in children // Ann. NY Acad. Sci. – 2004; 1033: 42–51.
- Seim H., Eichler K., Kleber H. L(-)-Carnitine and its precursor, gamma- butyrobetaine. In: Kramer K., Hoppe P., Packer L., eds. Nutraceuticals in Health and Disease Prevention / New York: Marcel Dekker, Inc, 2001; 217–56.
- Pons R., De Vivo D. Primary and secondary carnitine deficiency syndromes // J. Child Neurol. – 1995; 10 (Suppl. 2): 8–24.
- Calvani M., Benatti P., Mancinelli A. et al. Carnitine replacement in end-stage renal disease and hemodialysis // Ann. NY Acad. Sci. – 2004; 1033: 52–66.
- Food and Nutrition Board, Institute of Medicine. Vitamin C. Dietary Reference Intakes for Vitamin C, Vitamin E, Selenium, and Carotenoids / Washington D.C.: National Academy Press, 2000; 95–185.
- Costell M., O'Connor J., Grisolia S. Age-dependent decrease of carnitine content in muscle of mice and humans // Biochem. Biophys. Res. Commun. – 1989; 161 (3): 1135–43.
- Hagen T., Ingersoll R., Wehr C. et al. Acetyl-L-carnitine fed to old rats partially restores mitochondrial function and ambulatory activity // Proc. Natl. Acad. Sci. USA. – 1998; 95 (16): 9562–6.
- Pesce V., Fracasso F., Cassano P. et al. Acetyl-L-carnitine supplementation to old rats partially reverts the age- related mitochondrial decay of soleus muscle by activating peroxisome proliferator-activated receptor gamma coactivator-1alpha-dependent mitochondrial biogenesis // Rejuvenation Res. – 2010; 13 (2–3): 148–51.
- Gomez L., Heath S., Hagen T. Acetyl-l-carnitine supplementation reverses the age-related decline in carnitine palmitoyltransferase 1 (CPT1) activity in interfibrillar mitochondria without changing the l-carnitine content in the rat heart // Mech. Ageing Dev. – 2012; 133 (2–3): 99–106.
- Hagen T., Liu J., Lykkesfeldt J. et al. Feeding acetyl-L-carnitine and lipoic acid to old rats significantly improves metabolic function while decreasing oxidative stress // Proc. Natl. Acad. Sci. USA. – 2002; 99 (4): 1870–5.
- Liu J., Head E., Gharib A. et al. Memory loss in old rats is associated with brain mitochondrial decay and RNA/DNA oxidation: partial reversal by feeding acetyl-L-carnitine and/or R-alphalipoic acid // Proc. Natl. Acad. Sci. USA. – 2002; 99 (4): 2356–61.
- Davini P., Bigalli A., Lamanna F. et al. Controlled study on L-carnitine therapeutic efficacy in post-infarction // Drugs Exp. Clin. Res. – 1992; 18 (8): 355–65.
- Xue Y., Wang L., Liu H. et al. L-carnitine as an adjunct therapy to percutaneous coronary intervention for non-ST elevation myocardial infarction // Cardiovasc. Drugs Ther. – 2007; 21 (6): 445–8.
- Iyer R., Gupta A., Khan A. et al. Does left ventricular function improve with L-carnitine after acute myocardial infarction? // J. Postgrad. Med. – 1999; 45 (2): 38–41.
- Colonna P., Iliceto S. Myocardial infarction and left ventricular remodeling: results of the CEDIM trial. Carnitine Ecocardiografia Digitalizzata Infarto Miocardico // Am. Heart J. – 2000; 139 (2 Pt. 3): 124–30.
- Iliceto S., Scrutinio D., Bruzzi P. et al. Effects of L-carnitine administration on left ventricular remodeling after acute anterior myocardial infarction: the L-Carnitine Ecocardiografia Digitalizzata Infarto Miocardico (CEDIM) Trial // J. Am. Coll. Cardiol. – 1995; 26 (2): 380–7.
- Tarantini G., Scrutinio D., Bruzzi P. et al. Metabolic treatment with L-Carnitine in acute anterior ST segment elevation myocardial infarction. A randomized controlled trial // Cardiology. – 2006; 106 (4): 215–23.
- Semigolovskij N.Ju. Vertsinskij E.K., Azanov B.A. i dr. Polozhitel'nye inotropnye svojstva levokarnitina pri sindrome malogo vybrosa u bol'nyh ostrym infarktom miokarda // Kardiologija i serdechno-sosudistaja hirurgija. – 2013; 3: 43–6 [Semigolovskiy N.Yu., Vertinskiy E.K., Azanov B.A. et al. Positive inotropic properties of levocarnitine in low ejection syndrome among patients wiht acute myocardial infarction // Cardiology and Cardiovascular Surgery. – 2013; 3: 43–6 (in Russ.)].
- Glezer M.G., Kiseleva A.E., Astashkin E.I. Vlijanie L-karnitina na dispersiju intervala QT u patsientov s ostrym koronarnym sindromom // Kardiologija. – 2015; 55 (3): 4–9 [Gleser M.G., Kiseleva A.E., Astashkin E.I. The effect of L-carnitine on the dispersion of the QT interval in patients with acute coronary syndrome // Cardiology. – 2015; 55 (3): 4–9 (in Russ.)].
- Glezer M.G., Kiseleva A.E., Astashkin E.I. Vlijanie L-karnitina na ChCC i QTc u patsientov s ostrym koronarnym sindromom // Serdtse. – 2015; 14 (2/82): 78–84 [Glezer M.G., Kiseleva A.E., Astashkin E.I. Effect of L-carnitine on CV and QTc in patients with acute coronary syndrome // The Heart. – 2015; 14 (2/82): 78–84 (in Russ.)].
- Glezer M.G., Kiseleva A.E., Prokof'eva E.B. i dr. Vlijanie L-karnitina na ehokardiograficheskie pokazateli u patsientov s ostrym koronarnym sindromom // Serdechnaja nedostatochnost'. – 2015; 16 (4): 234–40 [Glezer M.G., Kiseleva A.E., Prokofieva E.B. et al. Effect of L-carnitine on echocardiographic parameters in patients with acute coronary syndrome // Heart Failure J. – 2015; 16 (4): 234–40 (in Russ.)].
- Astashkin E.I., Glezer M.G. Vlijanie L-karnitina na oksidativnyj stress pri serdechno-sosudistyh zabolevanijah // Med. sovet. – 2016; 10: 94–100 [Astashkin E.I., Glezer M.G. The effect of L-carnitine on oxidative stress in cardiovascular diseases // Medical advice. – 2016; 10: 94–100 (in Russ.)].
- Astashkin E.I., Glezer M.G., Orehova N.S. i dr. Vlijanie L-karnitina na obrazovanie radikalov kisloroda fagotsitami krovi patsientov s postinfarktnym kardiosklerozom // Kardiovaskuljarnaja terapija i profilaktika. – 2016; 15 (5): 28–32 [Astashkin E.I., Glezer M.G., Orekhova N.S. et al. Influence of L-carnitine on reactive oxygen species production by blood phagocytes in postinfarction cardiosclerosis patients // Cardiovascular therapy and prevention. – 2016; 15 (5): 28–32 (in Russ.)].
- Rizos I. Threeyear survival of patients with heart failure caused by dilated cardiomyopathy and L-carnitine administration // Am. Heart J. – 2000; 139 (2 Pt. 3): 120–3.
- Xiaolong Song, Huiyan Qu, Zongguo Yang et al. Efficacy and Safety of L-Carnitine Treatment for Chronic Heart Failure: A Meta-Analysis of Randomized Controlled Trials // BioMed Research International. – 2017; 2017: Article ID 6274854, 11 p. DOI: 10.1155/2017/6274854.
- Cacciatore L., Cerio R., Ciarimboli M. et al. The therapeutic effect of L-carnitine in patients with exercise-induced stable angina: a controlled study // Drugs Exp. Clin. Res. – 1991; 17 (4): 225–35.
- Cherchi A., Lai C., Angelino F. et al. Effects of L-carnitine on exercise tolerance in chronic stable angina: a multicenter, double-blind, randomized, placebo controlled crossover study // Int. J. Clin. Pharmacol. Ther. Toxicol. – 1985; 23 (10): 569–72.
- Iyer R., Khan A., Gupta A. et al. L-carnitine moderately improves the exercise tolerance in chronic stable angina // J. Assoc. Physicians India. – 2000; 48 (11): 1050–2.
- DiNicolantonio J., Lavie C., Fares H. et al. L-carnitine in the secondary prevention of cardiovascular disease: systematic review and metaanalysis // Mayo Clin. Proc. – 2013; 88 (6): 544–51.
- Guarnieri G., Situlin R., Biolo G. Carnitine metabolism in uremia // Am. J. Kidney Dis. – 2001; 38 (4 Suppl. 1): 63–7.
- Hurot J., Cucherat M., Haugh M. et al. Effects of L-carnitine supplementation in maintenance hemodialysis patients: a systematic review // J. Am. Soc. Nephrol. – 2002; 13 (3): 708–14.
- Kazmi W., Obrador G., Sternberg M. et al. Carnitine therapy is associated with decreased hospital utilization among hemodialysis patients // Am. J. Nephrol. – 2005; 25 (2): 106–15.
- Weinhandl E., Rao M., Gilbertson D. et al. Protective effect of intravenous levocarnitine on subsequent-month hospitalization among prevalent hemodialysis patients, 1998 to 2003 // Am. J. Kidney Dis. – 2007; 50 (5): 803–12.
- Clinical practice guidelines for nutrition in chronic renal failure. K/DOQI, National Kidney Foundation // Am. J. Kidney Diseases. – 2000; 35 (6 Suppl. 2): 1–140.
- Eknoyan G., Latos D., Lindberg J. Practice recommendations for the use of L-carnitine in dialysis-related carnitine disorder. National Kidney Foundation Carnitine Consensus Conference // Am. J. Kidney Dis. – 2003; 41 (4): 868–76.
- Schreiber B. Safety of oral carnitine in dialysis patients // Semin Dial. – 2002; 15 (1): 7.
- Wei X.-J., Han M., Wei G.-C. et al. Prognostic value of cerebrospinal fluid free fatty acid levels in patients with acute ischemic stroke // Frontiers in Human Neuroscience. – 2015; 9: 402. DOI: 10.3389/fnhum.2015.00402.
- Golovkin V., Zuev A., Privalova M. i dr. Kognitivnye narushenija i kardiorespiratornaja disfunktsija pri distsirkuljatornoj entsefalopatii s kardiotserebral'nym sindromom // Vrach. – 2018; 29 (4): 51–3 [Golovkin V., Zuev A., Privalova M. et al. Cognitive impairment and cardiorespiratory dysfunction in dyscirculatory encephalopathy with cardiocerebral syndrome // Vrach (The Doctor). – 2018; 29 (4): 51–3 (in Russ.)]. DOI: 10.29296/25877305-2018-04-09.
- Gusev E.I., Kuzin V.M., Kolesnikova T.N. i dr. Karnitin – veduschij faktor regeneratsii nervnoj tkani // Meditsinskij informatsionnyj vestnik. – 1999 (fevral'): 11–23 [Gusev E., Kuzin V.M., Kolesnikova T.N. Carnitine is a leading factor in the regeneration of nervous tissue // Medical Information Bulletin. – 1999 (February): 11–23 (in Russ.)].
- Bodyhov M.K., Stahovskaja L.V., Salimov K.A. i dr. Otsenka bezopasnosti i effektivnosti preparata «El'kar» (levokarnitin) u patsientov v ostrom periode ishemicheskogo insul'ta v karotidnoj sisteme // RMZh. Nevrologija. – 2011; 11: 3–6 [Bodikhov M.K., Stakhovskaya L.V., Salimov K.A. et al. Evaluation of the safety and efficacy of the drug Elkar (l-carnitine) in patients with acute ischemic stroke in the carotid system // RMZh. Neurology. – 2011; 11: 3–6 (in Russ.)].
- Chichanovskaja L.V., Bahareva O.N., Sorokina K.B. Issledovanie bezopasnosti i effektivnosti L-karnitina u bol'nyh v rannem vosstanovitel'nom periode ishemicheskogo insul'ta // Zhurnal nevrologii i psihiatrii im. S.S. Korsakova. – 2017; 12 (Vyp. 2): 65–9 [Chichanovskaya L.V., Bakhareva O.N., Sorokina K.B. The study of the safety and efficacy of L-carnitine in patients in the early recovery period of ischemic stroke // J. Neurology and Psychiatry named after SS Korsakov. – 2017; 12 (Vol. 2): 65–9 (in Russ.)].
- Makhova A., Shich E., Kukes V. etal. Electroanalysis of cytochrome P450 3A4 catalytic properties with nanostructured electrodes: the influence of vitamin B group on diclofenac metabolism // BioNanoScience. – 2011; 1 (1–2): 46–52.
- Mahova A.A., Shumjantseva V.V., Shih E.V. i dr. Reguljatsija aktivnosti fermentov metabolizma lekarstvennyh preparatov – tsitohromov R450 3A4 i 2S9 – biologicheski aktivnymi soedinenijami // Molekuljarnaja meditsina. – 2013; 5: 49–53 [Makhova A.A., Shumyantseva V.V., Shikh E.V. et al. Regulation of the activity of drug metabolism enzymes – cytochromes P450 3A4 and 2C9 – biologically active compounds // Molecular medicine. – 2013; 5: 49–53 (in Russ.)].